News
Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, in-vivo digital imaging at the single-cell level.
We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.
Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Stockhead TV
Long Shortz with Optiscan Imaging: To the US – and the moon!
Health & Biotech
Medtech Optiscan beefs up operations in US, hires two high-level execs
Health & Biotech
These ASX biotechs want to tackle cancer head-on for better outcomes
Long Shortz with Optiscan: Optiscan optimises AI in its fight against GI baddies
News
ASX Quarterly Wrap: RLF AgTech in positive territory, Optiscan cash receipts more than double
Stockhead TV
What’s in store for 2024: Optiscan
Tech
Stock Insiders: Optiscan is expanding and the potential is enormous
Tech
Optiscan’s platform could address global pathologist shortage
News
Quarterly wrap: YPB metrics continue to improve as it pursues profitability
Health & Biotech
‘Diagnose on the spot’: Optiscan’s platform brings together surgeons and pathologists for better cancer outcomes
News
In Case You Missed It: A bumper brain cancer trial and solid lithium hits
Health & Biotech
4D Medical’s technology disrupts century-old procedures AND makes over 90pc profit margin
News
After Neuren’s success, which other ASX health stocks are knocking on the US FDA door?
Health & Biotech
ASX Health Stocks: Patrys’ drug exhibits cancer lethality, US Patent Office says yes to Alterity
News
Market Highlights: Gold, Bitcoin sharply up as US bank stocks crumble, and 5 ASX small caps to watch today
Health & Biotech
ASX Biotech Stocks: Estia picks up 4 new aged care homes; MGC flags positive result for long COVID symptoms
News